We are live on ! Find out more
GALT icon

Galectin Therapeutics
GALT

58 hedge funds and large institutions have $5.88M invested in Galectin Therapeutics in 2015 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 15 increasing their positions, 14 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,022% more call options, than puts

Call options by funds: $819K | Put options by funds: $73K

175% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 4

14% more funds holding

Funds holding: 51 → 58 (+7)

7% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 14

16% less capital invested

Capital invested by funds: $7.02M → $5.88M (-$1.14M)

Holders
58
Holders Change
+7
Holders Change %
+13.73%
% of All Funds
1.52%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
15
Reduced
14
Closed
4
Calls
$819K
Puts
$73K
Net Calls
+$746K
Net Calls Change
+$827K

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$2.49M
2
DADC
D.A. Davidson & Co
Montana
+$133K
3
FIM
Freedom Investment Management
Connecticut
+$83.8K
4
ARTA
A.R.T. Advisors
New York
+$74.1K
5
AIG
American International Group
New York
+$73.3K

Top Sellers

Rank Fund Capital Flow
1
CAM
Cormorant Asset Management
Massachusetts
-$670K
2
Neuberger Berman Group
Neuberger Berman Group
New York
-$149K
3
Millennium Management
Millennium Management
New York
-$123K
4
Northern Trust
Northern Trust
Illinois
-$49.6K
5
Goldman Sachs
Goldman Sachs
New York
-$43.5K
Name Holding Trade Value Shares
Change 		Change in
Stake
SIM
26
Spark Investment Management
New York
$39K +$54.6K +23,854 New
California Public Employees Retirement System
27
California Public Employees Retirement System
California
$38K – – –
BTS
28
BB&T Securities
Virginia
$38K +$53.8K +23,500 New
Millennium Management
29
Millennium Management
New York
$30K -$123K -53,866 -75%
SWP
30
Stratos Wealth Partners
Ohio
$30K +$19.2K +8,400 +84%
RBC
31
Ronald Blue & Co
Georgia
$26K – – –
RG
32
Rathbones Group
United Kingdom
$21K – – –
BFM
33
Boothbay Fund Management
New York
$21K +$29K +12,670 New
State Street
34
State Street
Massachusetts
$18K – – –
Bank of America
35
Bank of America
North Carolina
$17K -$15.2K -6,640 -39%
Morgan Stanley
36
Morgan Stanley
New York
$17K -$8.73K -3,813 -27%
New York State Common Retirement Fund
37
New York State Common Retirement Fund
New York
$17K – – –
TRCT
38
Tower Research Capital (TRC)
New York
$15K +$19.6K +8,538 +2,556%
GT
39
Glenmede Trust
Pennsylvania
$13K – – –
Simplex Trading
40
Simplex Trading
Illinois
$13K +$18.8K +8,229 +16,458%
IA
41
IFP Advisors
Florida
$12K +$17.1K +7,450 New
WAM
42
Wolverine Asset Management
Illinois
$11K – – –
Deutsche Bank
43
Deutsche Bank
Germany
$8K +$9.13K +3,986 +266%
Wells Fargo
44
Wells Fargo
California
$6K -$1.9K -830 -18%
BIM
45
BlackRock Investment Management
Delaware
$6K +$877 +383 +12%
WP
46
WealthPLAN Partners
Nebraska
$4.11K +$17.2K +7,500 New
First Manhattan
47
First Manhattan
New York
$2K – – –
Walleye Trading
48
Walleye Trading
New York
$2K +$2.98K +1,300 New
Citigroup
49
Citigroup
New York
$2K +$3.04K +1,325 New
LTFS
50
Ladenburg Thalmann Financial Services
Florida
$1K – – –
1
2
3

GALT Hedge Fund Activity: Q4 2015 in Review

58 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q4 2015, worth a combined $5.88M — down 16% from $7.02M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new GALT positions and 4 closed out — a net gain of 7 holders — while 15 added to existing stakes and 14 trimmed.

The largest buyer was Sabby Management, opening a new position worth an estimated $2.49M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $670K sold.

  • 58 institutional investors held Galectin Therapeutics (GALT) as of Q4 2015, up from 51 in Q3 2015.
  • Funds reported $5.88M of Galectin Therapeutics stock for Q4 2015, down 16% quarter-over-quarter.
  • 11 funds opened new Galectin Therapeutics positions in Q4 2015 and 4 closed out, a net change of +7 holders.
  • The largest Galectin Therapeutics buyer in Q4 2015 was Sabby Management, an estimated $2.49M added.
  • The largest Galectin Therapeutics seller in Q4 2015 was Cormorant Asset Management, an estimated $670K sold.

Based on aggregated 13F filings for Q4 2015.